Articles Related to Candida albicans
Antibodies Anti-Proteins of Larrea Divaricata Cav. Present Opsonic Capacity on Candida Albicans Atcc 36801 and Neutralize its Cytotoxic and Immunoevasive Properties
Candida albicans is an opportunistic agent that can produce systemic infections in immunosuppressed patients. By varying
its cell wall antigens this fungus can evade the immunological response by varying its cell wall antigens. On the other hand,
Larrea divaricata Cav. (Jarilla) is a widely spread plant in America and it is used in folk medicine to treat several pathologies.
It has been shown that antibodies against Jarilla proteins of crude extract (JPCE) cross-react with proteins of other microorganisms such as Gram-negative bacteria.
In Vitro Models to Study Candida Albicans Biofilms
Biofilm is a common mode of fungal growth in clinical infection and Candida albicans is one of the species that are the most frequently associated with biofilm infection which has a significant impact on morbidity and mortality. In the mode of biofilm, C. albicans tends to display high resistance to body immunity and antimicrobial agents.
SLNs Based on Co-Processed Lipids for Topical Delivery of Terbinafine Hydrochloride
Terbinafine hydrochloride (TH) is first line drug against treatment of onychomycosis; which is the commonest fungal infection of nail plate. However, strong barrier property of nail plate restricts the effective topical treatment of onychomycosis. In this study, TH loaded solid lipid nanoparticles (SLNs) were prepared and subsequently incorporated into a gel system. SLNs were prepared by high pressure homogenization (HPH) technique using glyceryl monosterate (GMS), compritol 888ATO and a co-processed lipid. They were evaluated for particle size, polydispersity index, zeta potential, % entrapment efficiency (%EE), % drug loading (%DL), drug content and in-vitro drug release. Optimized SLNs were incorporated into chitosan gel and further evaluated for in-vitro drug release and ex-vivo antifungal study.
Reduction of Bitterness and Enhancing Palatability of Cetirizine Oral Liquid Dosage Forms by Cyclodextrins
The aim of this manuscript is to study cyclodextrins (CDs) as a potential excipient to suppress bitterness and enhance palatability of pediatric liquid preparations for Cetirizine, an extremely bitter drug. Natural α, β and γ CDs; and β CD derivatives such as hydroxyl propyl (HP), randomly methylated (RM) and sulfobutyl ether (SBE) β-CDs were screened in different molar ratios of 1:1, 1:2 and 1:3 for their inhibition of the extremely bitter taste of Cetirizine using the human gustatory sensation test.